Compare · JNJ vs PRGO
JNJ vs PRGO
Side-by-side comparison of Johnson & Johnson (JNJ) and Perrigo Company plc (PRGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PRGO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 266.9x PRGO ($2.29B).
- Over the past year, JNJ is up 32.3% and PRGO is down 23.1% - JNJ leads by 55.3 points.
- JNJ has hit the wire 16 times in the past 4 weeks while PRGO has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 11 for PRGO).
- Company
- Johnson & Johnson
- Perrigo Company plc
- Price
- $255.53+0.88%
- $16.63+0.76%
- Market cap
- $610.38B
- $2.29B
- 1M return
- -5.45%
- +23.29%
- 1Y return
- +32.25%
- -23.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 11
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Latest PRGO
- Director Parker Geoffrey M. covered exercise/tax liability with 607 units of Ordinary Shares and exercised 1,263 units of Ordinary Shares at a strike of $13.66, increasing direct ownership by 2% to 33,873 units (SEC Form 4)
- Director Alford Bradley A exercised 1,263 units of Ordinary Shares at a strike of $13.66 and covered exercise/tax liability with 607 units of Ordinary Shares, increasing direct ownership by 1% to 46,121 units (SEC Form 4)
- EVP & CBDO Ball David exercised 7,701 units of Ordinary Shares at a strike of $14.34 and covered exercise/tax liability with 2,784 units of Ordinary Shares, increasing direct ownership by 73% to 11,664 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc
- Perrigo to Attend the Barclays Global Consumer Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc
- SEC Form 10-Q filed by Perrigo Company plc
- Perrigo Company plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations
- Perrigo Announces Quarterly Dividend